Furthermore, TGF-β as EV cargo has been linked to transfer of resistance to anti-cancer drugs in head-and-neck squamous cell carcinoma and BRCA [15, 53], a phenotype that here was partially inhibitable by a TGF-β type I receptor inhibitor. This evidence concerns the gene TGFB1 and head and neck squamous cell carcinoma.